Understanding Lewy Bodies in Neurodegeneration
A deep dive into Lewy bodies and their impact on brain health.
Liam Horan-Portelance, Michiyo Iba, Dominic J. Acri, J. Raphael Gibbs, Mark R. Cookson
― 7 min read
Table of Contents
- What are Lewy Bodies?
- The Pathology Puzzle
- Neurons and Their Vulnerabilities
- What's Going Wrong at the Molecular Level?
- New Tools to Study the Problem
- The Mouse Model Investigation
- A Closer Look at Cell Types
- So What’s the Deal with Plk2?
- Moving Beyond Just Alpha-synuclein
- A Broader Perspective on Brain Health
- What’s Next?
- Conclusion
- Original Source
- Reference Links
Parkinson’s disease (PD) and dementia with Lewy Bodies (DLB) are two related brain disorders that share some common features. Both conditions involve the buildup of a protein called Alpha-synuclein, which can misfold and form aggregates in the brain. This buildup can lead to various problems in the brain cells and create challenges in how the brain works.
What are Lewy Bodies?
Lewy bodies are clumps of misfolded alpha-synuclein protein that gather inside nerve cells. These clumps can disrupt normal cell function and eventually lead to cell death. Imagine if your computer started gathering junk files that slowed it down; that’s similar to what happens in the brain due to Lewy bodies.
The Pathology Puzzle
Researchers have been trying to figure out whether the presence of Lewy bodies directly causes the symptoms of PD and DLB or if they simply show up as a byproduct of other issues going on in the brain. Some studies have shown that these clumps could harm brain cells, leading to problems with how they work. But other observations have confused researchers. For instance, some people with many Lewy bodies may not show any cognitive problems. This raises a question: Is the presence of Lewy bodies a sign of trouble or just an innocent bystander?
Neurons and Their Vulnerabilities
In the brain, not all neurons are created equal. Some are more sensitive to damage than others. For example, in PD, the neurons in the deep parts of the brain are the first to develop problems with Lewy bodies. As the disease progresses, these issues spread to the midbrain and eventually the outer layers of the brain.
Interestingly, while many neurons in the substantia nigra (an important part of the brain for motor control) develop lots of Lewy bodies, nearby neurons in another region called the ventral tegmental area seem to resist this pathology. Yes, it’s like living next door to someone who’s always getting into trouble, while you get to sit back and relax. So why are some neurons more resistant?
What's Going Wrong at the Molecular Level?
Although researchers have identified certain neurons that are more vulnerable to these protein clumps, they still don't fully understand why. Some evidence suggests that the level of alpha-synuclein naturally present in the neurons might play a role. Neurons that produce more of this protein seem to be at higher risk for developing issues.
However, the relationship isn’t straightforward. For example, two types of neurons that express high levels of alpha-synuclein can behave very differently when it comes to vulnerability to damage. Moreover, some cells, like oligodendrocytes, which normally have low levels of alpha-synuclein, can still accumulate the misfolded protein in certain disorders.
Researchers have also suggested that other factors, like how well neurons are connected to each other, the insulation of their wires (myelination), and how they manage calcium levels, can influence their resilience or vulnerability.
New Tools to Study the Problem
Recent advances in technology are allowing researchers to look more closely at brain cells and their environments. New methods let scientists see the expression of hundreds of genes at once in living brain tissue. This approach allows researchers to explore how different brain cells respond to alpha-synuclein and figure out which brain cells are vulnerable and which are not.
A popular tool for this is called spatial transcriptomics, which combines imaging with gene expression measurements. This means scientists can visualize not only how the cells look but also what genes are active in each of those cells, helping to create a more detailed picture of what’s going on.
The Mouse Model Investigation
To better understand how these brain processes work in PD, scientists often use mouse models. In one telling study, researchers used mice that overexpress a form of human alpha-synuclein, closely mimicking the conditions found in human brains affected by PD. This allowed them to look at the differences in gene expression between neurons that develop Lewy body pathology and those that do not.
After studying these mice, researchers discovered what types of neurons were most affected by the formation of Lewy bodies. They found that excitatory neurons (the neurons that send signals in the brain) were particularly prone to developing these clumps, while inhibitory neurons (the ones that calm things down) generally stayed clear of the pathology.
A Closer Look at Cell Types
Throughout their study, researchers identified various types of neurons and observed their unique vulnerabilities to Lewy bodies. They noticed that while excitatory neurons were widely affected, inhibitory neurons seemed to be spared, even though they expressed high levels of alpha-synuclein.
The research also revealed differences among excitatory neurons. For instance, a specific type of neuron in the outer layers of the brain, called L5 ET (extratelencephalic), showed high levels of pathology compared to L5 IT neurons, even though both types expressed similar amounts of alpha-synuclein. This suggests other factors are at play when it comes to vulnerability.
So What’s the Deal with Plk2?
One potential contributor to this vulnerability is a protein called Plk2. Plk2 is known for phosphorylating alpha-synuclein, which can influence the protein’s behavior and its ability to form clumps. In their studies, researchers found that cells expressing higher levels of Plk2 were more likely to develop Lewy bodies.
Interestingly, while many alterations in gene expression linked to protein management were observed, Plk2 emerged as a critical player in the process of how neurons respond to the buildup of alpha-synuclein. In essence, neurons that manage to express Plk2 effectively might be at an advantage, while those that don’t could be on the road to trouble.
Moving Beyond Just Alpha-synuclein
As the researchers explored the Transcriptional effects of alpha-synuclein overexpression and the presence of Lewy bodies, they uncovered not only the expected changes in genes related to alpha-synuclein but also additional genes linked to cellular health. They observed that the expression levels of important chaperones and autophagy-related genes went down, hinting at a broader problem with protein management in these neurons.
This shift in gene expression might cause a cascade of issues, leading to cellular stress and eventually cell death. So while the focus has been on alpha-synuclein, it’s clear that the overall health of the neurons must also be monitored.
A Broader Perspective on Brain Health
Through their investigation, researchers uncovered not just the mechanics of protein malfunction but the broader implications for brain health. Their studies highlighted the idea that even neurons that do not show visible signs of damage might still be struggling internally. This is akin to a visible flower that appears healthy on the outside but may have a root problem underground.
What’s Next?
While the findings of these studies bring valuable insights into the mechanisms of PD and DLB, there is still much work to be done. Future studies will continue to explore the roles of various proteins, the interplay between different types of neurons, and the overall environment in which they exist.
With time and more research, scientists hope to unravel the complexities of these diseases and identify potential treatments that target not just the symptoms but also the underlying causes of neuronal damage.
Conclusion
In the ongoing battle against neurodegenerative diseases, a better understanding of how specific brain cells respond to damaging proteins like alpha-synuclein is crucial. By employing advanced techniques and models, researchers are painting a clearer picture of these complex conditions, one that holds the potential for new therapeutic approaches.
So, the next time someone mentions Parkinson’s disease or Lewy body dementia, remember that it’s not just about the clumps; it’s about the whole orchestra of neurons and how they play together. And with continued research, we may just find the right conductor to get the music playing harmoniously again.
Original Source
Title: Imaging spatial transcriptomics reveals molecular patterns of vulnerability to pathology in a transgenic α-synucleinopathy model
Abstract: In Parkinsons disease and dementia with Lewy bodies, aggregated and phosphorylated -synuclein pathology appears in select neurons throughout cortical and subcortical regions, but little is currently known about why certain populations are selectively vulnerable. Here, using imaging spatial transcriptomics (IST) coupled with downstream immunofluorescence for -synuclein phosphorylated at Ser129 (pSyn) in the same tissue sections, we identified neuronal subtypes in the cortex and hippocampus of transgenic human -synuclein-overexpressing mice that preferentially developed pSyn pathology. Additionally, we investigated the transcriptional underpinnings of this vulnerability, pointing to expression of Plk2, which phosphorylates -synuclein at Ser129, and human SNCA (hSNCA), as key to pSyn pathology development. Finally, we performed differential expression analysis, revealing gene expression changes broadly downstream of hSNCA overexpression, as well as pSyn-dependent alterations in mitochondrial and endolysosomal genes. Overall, this study yields new insights into the formation of -synuclein pathology and its downstream effects in a synucleinopathy mouse model.
Authors: Liam Horan-Portelance, Michiyo Iba, Dominic J. Acri, J. Raphael Gibbs, Mark R. Cookson
Last Update: 2024-12-14 00:00:00
Language: English
Source URL: https://www.biorxiv.org/content/10.1101/2024.07.31.606032
Source PDF: https://www.biorxiv.org/content/10.1101/2024.07.31.606032.full.pdf
Licence: https://creativecommons.org/publicdomain/zero/1.0/
Changes: This summary was created with assistance from AI and may have inaccuracies. For accurate information, please refer to the original source documents linked here.
Thank you to biorxiv for use of its open access interoperability.